Novartis AG
Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy
Last updated:
Abstract:
The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
Status:
Grant
Type:
Utility
Filling date:
11 Oct 2017
Issue date:
28 Jul 2020